Cellceutix Receives IRB Approval for Phase 2b Trial of Novel Antibiotic Brilacidin
BEVERLY, MA—January 13, 2014 – Cellceutix Corporation (OTCQB: CTIX) (the “Company”), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, today announced that the Company will be presenting a corporate overview at the Biotech Showcase(TM) 2014 on Wednesday, January 15th, at 10:30 a.m. PST. The conference is being held in San Francisco at the Parc 55 Wyndham Union Square Hotel.
Interested parties may access the live webcast of the presentation at: http://cellceutix.com/events/ or http://www.media-server.com/m/p/ad4gm88c. A webcast replay will be available approximately two hours after the presentation ends.
The Company is also updating shareholders that it has received Institutional Review Board (“IRB”) approval for the Company’s Phase 2b clinical trial of its novel antibiotic Brilacidin as a drug candidate for Acute Bacterial Skin and Skin Structure Infections (“ABSSSI”). Further details will be forthcoming at the Biotech Showcase presentation.